Jack Harkness and Lenore Furgler’s business relationship

Jack Harkness and Lenore Furgler’s business relationship began with Harkness as her personal assistant and culminated in her sale of Furgler Gesellschaft to him. Lenore’s confidence in him carried him into the company’s leadership despite her family’s distrust, and the transfer made him the head of the business that became Harkness Pharmaceuticals.

From assistant to strategist

Lenore had recently inherited control of Furgler Gesellschaft, a medium-sized pharmaceutical company based in Basel, from her father. Harkness appeared in Switzerland after several years of travel during which his whereabouts were unclear. He became Lenore’s personal assistant, then, during the 1980s, secured a seat on the company’s board with responsibility for strategy. The account presents his advancement as a consequence of Lenore’s trust in him, while making clear that her confidence was not shared by the rest of the family.

Lenore was widowed and had three sons who expected eventually to take control of the company and dismiss Harkness. That anticipated succession never occurred. Instead, Harkness remained in place long enough to become the buyer when Lenore decided to sell.

The 1995 transfer

By 1995, Lenore was ailing, and the question of what would happen to the company had become pressing. She sold Furgler Gesellschaft to Harkness. The sale price was described as neither a premium nor a negligible amount, but the source of Harkness’s funds was not established. Rumors suggested that he had borrowed from Vladimir Drishkov, a Russian oligarch whose mining corporation was said to have been corruptly acquired. Drishkov was shot dead by unidentified assassins a few months later; the account does not establish any connection between his death and the sale or explain whether his alleged loan financed it.

The transaction decisively altered their professional relationship: Harkness ceased to be an employee serving under Lenore and became the company’s owner. The narrative gives no further account of their dealings after the sale, so Lenore’s role is most clearly defined by the trust that enabled his ascent and the transfer that placed the company in his hands.

The company after Lenore

Under Harkness, the company took the name Harkness Pharmaceuticals and expanded rapidly. He opened a dedicated research laboratory in Locarno, where Filippo Crosetti developed beauty-treatment products, culminating in Elixtris, an anti-ageing cream released in 2009. A partnership with Quintagler Industries supported acquisitions of competitors across North America, Europe, and Asia. These later developments show the scale of the enterprise that grew from the 1995 transfer, but the evidence does not attribute the company’s subsequent strategy or products to Lenore.

The company’s later history also complicates the appearance of a straightforward business succession. Quintagler alleged that Harkness diverted funds through subsidiaries of shell companies he ultimately owned, with some allegedly used for bribes to doctors; investigators did not know where the rest of the alleged billions had gone. Separately, Harkness Pharmaceuticals products and other goods connected to the company became means of distributing nanobots as part of a concealed program. These revelations concern Harkness’s later control and aims, not Lenore’s involvement. Her significance in the relationship remains concentrated at the point where personal trust became corporate authority: she gave Harkness access to leadership, and ultimately sold him the company he would reshape.